Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Radiation Exposure in Chronic Total Occlusions

Even in the hands of experienced operators, rechanneling and angioplasty of a chronic total occlusion (CTO) results in patients and the whole cath lab team receiving high doses of radiation, according to this registry presented at the American Heart Association 2017 Scientific Sessions.
Exposición a la radiación en oclusiones totales crónicas

Up to 23% of patients who undergo rechanneling of a CTO receive a radiation dose greater than 5 Gy.


Read also: Protective Shield RADPAD Reduces the Radiation Dose Received by Operators in the Cath Lab”.


This study identified several clinical and angiographic factors that could help identify beforehand patients most at risk for receiving excess radiation. These factors include high body mass index, prior myocardial revascularization surgery, moderate to severe calcification, proximal cap ambiguity, and longer occlusion length.

 

All of these are both logical and expected to be in this list. On the one hand, high body mass index requires a higher radiation dose, and on the other hand, all other factors are well-known predictors of higher procedural difficulty.


Read also: Important Study Detects Radiation-Induced DNA Damage in Operators After an Endovascular Procedure”.


Measures such as changing fluoroscopy settings from start or the use of shielding may be helpful for patients who are likely to receive high radiation doses. Changing fluoroscopy settings or projection once we are past 2 Gy is definitely too late.

 

The PROGRESS-CTO registry was designed to get of a sense of patient radiation exposure during rechanneling procedures in contemporary practice. The current analysis included data on 1517 patients treated at 12 US centers between 2012 and 2017.

 

The air kerma radiation dose received by patients was relatively low (less than 2.1 Gy) in 33%, intermediate (2.1 to 5.0 Gy) in 44%, and high (greater than 5.0 Gy) in 23%.


Read also: Study Confirms Lead Shields Protect Cath Lab Staff from Radiation Exposure”.


The mean was 2.95 Gy, although there was a surprisingly substantial variation across centers. In fact, treatment at a few specific centers was predictive of a high radiation dose.

 

Fluoroscopy time was hand in hand with contrast volume and the rate of complications; however, it was inversely proportional to the rate of success. Despite different adjustments, this might just imply that certain centers chose simpler total occlusions.

 

In any case, worries about radiation should not factor into the decision to treat chronic total occlusions as clinically indicated.

 

Original title: Radiation Exposure of Patients During Chronic Total Occlusion Percutaneous Coronary Intervention. Update from a Contemporary Multicenter Registry.

Reference: Karacsonyi J. et al. Presented at the American Heart Association 2017 Scientific Sessions.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...